Pricing and Reimbursement

The OHE has published a report exploring the impact on payers, patients and innovators of differential prices for different uses of pharmaceuticals.

OHE Consulting produces a report critiquing a paper by Hill et al. (2018) on estimated costs of production for the WHO Essential Medicines List.

Meet some of the OHE team at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2018 conference in Baltimore, 19-23 May.

Just published are two new reports that explore the use of real world evidence for coverage and formulary decisions. The publications represent 1) the background paper to the 2017 ICER Membership Policy Summit and 2) a follow up paper based on the discussion at the Summit.

A recently published editorial by OHE’s David Mott considers whether quantitative patient preference data has a role to play in HTA decision making.

A recent issue of Value in Health contains the ISPOR Special Task Force Report on US Value Assessment Frameworks. In this blog post, we summarise the Task Force Report and pick up key points made in the various response articles. We also highlight further OHE work in this area.

This report analyses patient access in the UK to new medicines authorised via the centralised procedure between 2011 and 2016.

Drug prices in the US might overstate pharmaceuticals' long-run cost up to 75%. True long-term costs then must be considered by market access and policy decisions.

The presentations delivered by OHE at the iHEA congress, July 2017, are available in this post.

The presentations delivered by OHE at the HTAi Annual Meeting, June 2017, are available in this post.

Pages

Subscribe to RSS - Pricing and Reimbursement